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hybridised against female human genomic DNA to a high resolution 
array-Comparative Genomic Hybridisation (aCGH) platform contain-
ing ~43,000 probes (Agilent 44K Human Whole-Genome 44B arrays). 
Genomic regions with signiﬁcant copy-number variation (CNV) (DNA 
gain/loss) were identiﬁed using an aberration detection algorithm (CGH 
Analytics V3.4).
Results: The most frequent CNVs in current smokers were gain 
of 1q21.1-q24.2 and 5p15.33-p12 (>60% of tumours) and loss of 
8p23.3-p12 and 13q12.11-q34 (>20% of tumours). The most frequent 
CNVs in former smokers were gain at 1q25.2-q44 and 17q11.2-q25.3 
(>50% of tumours) and loss at 13q12.11-q21.2 and 21q11.2-q22.3 
(>20% of tumours). The most frequent CNVs in never smokers were 
gain at 7p22.3-p11.2 (>50% of tumours) and loss at 8p23.3-p11.22 
and 13q13.3-q14.3 (>50% of tumours). CNVs present in both current 
and former smokers were compared to identify recurrent (occurring in 
>30% of tumours, both smokers and former smokers) genomic aber-
rations. Frequent copy-number gain was observed at 1q21.1-q31.3, 
1q31.1-q44, 3q26.1-q29, 5p15.33-p12, 7p22.1-p11.2, 7p11.1-q36.2, 
and 17q21.2-q25.3. Gain at 1q25.2-q31.3 occurred in more than 50% 
of current and former smokers, yet was rarely gained in never-smokers 
(8%).
Conclusions: In the chaos that occurs in lung cancer cells that develop 
in current smokers (with continued carcinogenic exposure and therefore 
high lung cancer risk), those aberrations in common with lung cancer 
cells that develop in former smokers (with no further carcinogenic 
exposure and therefore lower but persistent lung cancer risk) may 
represent irreversible causative genetic damage. Genes located in these 
aberrations represent strong chemoprevention targets. Our analysis has 
identiﬁed several loci frequently aberrant in both current and former 
smokers. These loci are now being further studied to identify the poten-
tial gene targets of aberration.
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Objective: The Danish lung cancer screening trial is a randomized trial 
comparing CT screening with no screening. The trial is done with the 
NELSON trial in the Netherlands, Europe. The ﬁnal end point is lung 
cancer mortality.
Methods: From 2004 to 2006 4104 Danish smokers and previous 
smokers were randomized to either screening with annual low dose CT 
scans for 5 years or no screening. A history of cigarette smoking of at 
least 20 pack years was required. All had lung function tests, and ques-
tionnaires regarding psychosocial consequences of screening, smoking 
and smoking cessation at randomization and planned annually. 
All scans are performed with a 16 detector row CT scanner at low dose 
levels, and viewed independently by two board certiﬁed radiologists. 
Nodules identiﬁed in the baseline year were considered prevalence 
nodules. 
Nodules were classiﬁed according to size and other characteristic: 
• Nodules smaller than 5 mm and calciﬁed nodules with a maximal 
diameter up to 20 mm were just tabulated. 
• Uncalciﬁed nodules with a diameter between 5 and 15 mm were 
re-scanned after 3 months; 1) if the size was stable or reduced no 
further action was taken.2) If the nodule grew it was referred for 
invasive workup, as were uncalciﬁed nodules larger than 15 mm.
CT with contrast and PET CT was performed before any invasive 
procedures. 
Results: At baseline 177 persons had nodules larger than 5 mm on the 
ﬁrst scan, and almost all were rescanned after 3 months. 
• Seventeen individuals (0.8%) with a suspicious lung nodule were 
referred to surgical exploration and all turned out to have cancer. 
One stage IA patient had segmental resection (adenocarcinoma 
(ACL) dominated by BAC features), ten patients (6 stage IA, 3 stage 
IB and 1 stage IIIB) had lobectomy (9 ACL and 1 squamous cell 
carcinoma (SQC), one stage IIIA had pneumonectomy (ACL).The 
remaining ﬁve patients were in stage IIIA after diagnostic evaluation 
and received chemotherapy (3 non small cell lung carcer (NSCLC), 
probably ACL, 1 ACL, 1 SQC). 
• Seventy one percent had ACL, 12% SQC and 17% NSCLC. No 
SCLC was diagnosed.
• Twelve of 17 lung cancers at base line were treated surgically, 8 of 
these were treated by VATS resection.
• One participant had a benign hamartoma (4 cm) removed by VATS 
local resection and one had a diagnostic VATS on suspicion of me-
sothelioma which turned out to be pleural tuberculosis.
• Rate of false positive diagnoses was 8,6 %. 
• In the control group so far one patient had a lobectomy (ACL) stage 
1, one had a pneumonectomy for a stage IIIA lung cancer, two had 
oncological treatment for stage 4 disease (ACL) and one patient died 
with lung cancer stage IIIB (ACL). 
Conclusion: Screening facilitates minimal invasive treatment and can 
be performed with a low rate of false positive diagnoses. 
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